ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 145 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,706,875 | -28.7% | 687,135 | +7.9% | 0.02% | -34.8% |
| Q2 2023 | $6,603,917 | +91.7% | 636,829 | +49.6% | 0.02% | +91.7% |
| Q1 2023 | $3,444,949 | +112113.3% | 425,828 | +118.5% | 0.01% | +9.1% |
| Q4 2022 | $3,070 | -99.9% | 194,923 | 0.0% | 0.01% | -8.3% |
| Q3 2022 | $3,068,000 | -25.0% | 194,923 | -33.5% | 0.01% | -20.0% |
| Q2 2022 | $4,091,000 | -53.2% | 293,045 | -42.2% | 0.02% | -37.5% |
| Q1 2022 | $8,748,000 | +2.7% | 507,435 | +7.2% | 0.02% | -11.1% |
| Q3 2021 | $8,521,000 | -15.9% | 473,365 | -17.9% | 0.03% | -20.6% |
| Q2 2021 | $10,130,000 | +1851.8% | 576,872 | +2701.8% | 0.03% | +1600.0% |
| Q1 2021 | $519,000 | +185.2% | 20,589 | -75.2% | 0.00% | +100.0% |
| Q2 2019 | $182,000 | -79.6% | 82,905 | -31.5% | 0.00% | -90.0% |
| Q4 2018 | $894,000 | – | 121,011 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |